Please login to the form below

Not currently logged in
Email:
Password:

wet AMD

This page shows the latest wet AMD news and features for those working in and with pharma, biotech and healthcare.

NHS wins legal fight with pharma over off-label Avastin

NHS wins legal fight with pharma over off-label Avastin

and Novartis’Lucentis  to treat wet AMD, claiming that it broke EU and UK laws governing medicines licensing. ... CCGs across the country have been thwarted in their various attempts to introduce the cheaper but equally effective drug Avastin for the

Latest news

More from news
Approximately 19 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Pharma deals during May 2014 Pharma deals during May 2014

    Top of the list was Ophthotech's commercialisation and co-development agreement with Novartis for Fovista, an anti-PDGF agent, in phase 3 for wet age-related macular degeneration (AMD). ... Coincidentally two weeks earlier, there was another deal for a

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐ endoglin antibodies, including TRC105 for wet AMD (p2).

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    effectiveness over Novartis' Lucentis (ranibizumab) in the treatment of wet age-related macular degeneration (AMD).

  • Revolution or evolution: is it the end of SMR and ASMR in France? Revolution or evolution: is it the end of SMR and ASMR in France?

    An example of this is Lucentis in wet age-related macular degeneration (AMD), where the expectation is that there should be pricing parity between Lucentis and Avastin, an oncology drug used

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics